Skip to Main Content

Paper Details

Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in <i>BRCA2</i>-altered Prostate Tumors.
Clin Cancer Res
12
2021
3D, ATM, BRCA1, BRCA1/2, BRCA2, BRCA2 wild, BRCA2-altered Prostate Tumors, BRCA2-null prostate cancer cell lines, BRCA2-null prostate cancer cells, DDR, DNA damage, PARP, PARPi, PARPis, Rb1, SRC, SRC Kinase, Trp53, bosutinib, dasatinib, mCRPC, men, metastatic castration-resistant prostate cancer, null prostate cancer cells, patients, prostate cancer, saracatinib, wild-type cells
Author NameAffiliation
Wassim AbidaMemorial Sloan Kettering Cancer Center
Michael J MorrisMemorial Sloan Kettering Cancer Center
Lorelei A MucciHarvard T.H. Chan School of Public Health
Philip W KantoffMemorial Sloan Kettering Cancer Center
Philip W KantoffMemorial Sloan Kettering Cancer Center
  • 1 - 5

Datasets

Release 1.2